---
input_text: 'Association of Matched Sibling Donor Hematopoietic Stem Cell Transplantation
  With Transcranial Doppler Velocities in Children With Sickle Cell Anemia. Importance:
  In children with sickle cell anemia (SCA), high transcranial Doppler (TCD) velocities
  are associated with stroke risk, which is reduced by chronic transfusion. Whether
  matched sibling donor hematopoietic stem cell transplantation (MSD-HSCT) can reduce
  velocities in patients with SCA is unknown. Objective: To determine the association
  of MSD-HSCT with TCD velocities as a surrogate for the occurrence of ischemic stroke
  in children with SCA. Design, Setting, and Participants: Nonrandomized controlled
  intervention study conducted at 9 French centers. Patients with SCA were enrolled
  between December 2010 and June 2013, with 3-year follow-up ending in January 2017.
  Children with SCA were eligible if younger than 15 years, required chronic transfusions
  for persistently elevated TCD velocities, and had at least 1 sibling without SCA
  from the same 2 parents. Families agreed to HLA antigen typing and transplantation
  if a matched sibling donor was identified or to standard care in the absence of
  a matched sibling donor. Exposures: MSD-HSCT (n = 32), compared with standard care
  (n = 35) (transfusions for >=1 year with potential switch to hydroxyurea thereafter),
  using propensity score matching. Main Outcomes and Measures: The primary outcome
  was the highest time-averaged mean of maximum velocities in 8 cerebral arteries,
  measured by TCD (TCD velocity) at 1 year. Twenty-five of 29 secondary outcomes were
  analyzed, including the highest TCD velocity at 3 years and normalization of velocities
  (<170 cm/s) and ferritin levels at 1 and 3 years. Results: Sixty-seven children
  with SCA (median age, 7.6 years; 35 girls [52%]) were enrolled (7 with stroke history).
  In the matched sample, highest TCD velocities at 1 year were significantly lower
  on average in the transplantation group (129.6 cm/s) vs the standard care group
  (170.4 cm/s; difference, -40.8 cm/s [95% CI, -62.9 to -18.6]; P < .001). Of the
  25 analyzed secondary end points, 4 showed significant differences, including the
  highest TCD velocity at 3 years (112.4 cm/s in the transplantation group vs 156.7
  cm/s in the standard care group; difference, -44.3 [95% CI, -71.9 to -21.1]; P =
  .001); normalization rate at 1 year (80.0% in the transplantation group vs 48.0%
  in the standard care group; difference, 32.0% [95% CI, 0.2% to 58.6%]; P = .045);
  and ferritin levels at 1 year (905 ng/mL in the transplantation group vs 2529 ng/mL
  in the standard care group; difference, -1624 [95% CI, -2370 to -879]; P < .001)
  and 3 years (382 ng/mL in the transplantation group vs 2170 ng/mL in the standard
  care group; difference, -1788 [95% CI, -2570 to -1006]; P < .001). Conclusions and
  Relevance: Among children with SCA requiring chronic transfusion because of persistently
  elevated TCD velocities, MSD-HSCT was significantly associated with lower TCD velocities
  at 1 year compared with standard care. Further research is warranted to assess the
  effects of MSD-HSCT on clinical outcomes and over longer follow-up. Trial Registration:
  ClinicalTrials.gov Identifier: NCT01340404.'
raw_completion_output: |-
  primary_disease: Sickle Cell Anemia
  medical_actions: Matched sibling donor hematopoietic stem cell transplantation (MSD-HSCT); Chronic transfusion; Hydroxyurea treatment
  symptoms: High transcranial Doppler (TCD) velocities; Stroke risk; Persistently elevated TCD velocities
  chemicals: Hydroxyurea
  action_annotation_relationships: Matched sibling donor hematopoietic stem cell transplantation (MSD-HSCT) TREATS high transcranial Doppler (TCD) velocities IN Sickle Cell Anemia; Chronic transfusion TREATS High transcranial Doppler (TCD) velocities IN Sickle Cell Anemia; Hydroxyurea treatment (with Hydroxyurea) TREATS high transcranial Doppler (TCD) velocities IN Sickle Cell Anemia
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Hydroxyurea treatment (with Hydroxyurea) TREATS high transcranial Doppler (TCD) velocities IN Sickle Cell Anemia

  ===

extracted_object:
  primary_disease: MONDO:0011382
  medical_actions:
    - Matched sibling donor hematopoietic stem cell transplantation (MSD-HSCT)
    - Chronic transfusion
    - Hydroxyurea treatment
  symptoms:
    - HP:0001139
    - Stroke risk
    - Persistently elevated TCD velocities
  chemicals:
    - CHEBI:44423
  action_annotation_relationships:
    - subject: Matched sibling donor hematopoietic stem cell transplantation (MSD-HSCT)
      predicate: TREATS
      object: HP:0001139
      qualifier: MONDO:0011382
      subject_qualifier: matched sibling donor
      subject_extension: hematopoietic stem cell transplantation
    - subject: Chronic transfusion
      predicate: TREATS
      object: HP:0001139
      qualifier: MONDO:0011382
    - subject: Hydroxyurea treatment
      predicate: TREATS
      object: HP:0001139
      qualifier: MONDO:0011382
      subject_qualifier: with Hydroxyurea
      object_qualifier: high
      subject_extension: CHEBI:44423
      object_extension: high
named_entities:
  - id: MONDO:0011382
    label: sickle cell disease
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:35341
    label: steroids
  - id: CHEBI:81579
    label: erythropoietin
  - id: MAXO:0001017
    label: Vaccination
  - id: MONDO:0007374
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0000747
    label: Allogeneic hematopoietic stem cell transplantation (HSCT)
  - id: HP:0007760
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0001001
    label: Gene therapy
  - id: CHEBI:35480
    label: analgesics
  - id: CHEBI:33281
    label: antibiotics
  - id: MAXO:0001077
    label: Splenectomy
  - id: MAXO:0000756
    label: Blood transfusion
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: CHEBI:44423
    label: Hydroxyurea
  - id: HP:0001297
    label: Stroke
  - id: HP:0002863
    label: Myelodysplastic syndrome
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:82594
    label: Ferritin
  - id: MONDO:0000984
    label: thalassemia
  - id: MONDO:0018881
    label: myelodysplastic syndrome
  - id: HP:0002140
    label: Ischemic Stroke
  - id: MONDO:0005380
    label: avascular necrosis
  - id: MAXO:0009047
    label: total hip replacement
  - id: HP:0010885
    label: avascular necrosis
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: CHEBI:41879
    label: dexamethasone
  - id: CHEBI:9570
    label: thiotepa
  - id: CHEBI:125354
    label: plerixafor
  - id: CHEBI:9168
    label: sirolimus
  - id: CHEBI:8764
    label: mycophenolate mofetil
  - id: HP:0012531
    label: Pain
  - id: MAXO:0000515
    label: Extracorporeal life support
  - id: HP:0001708
    label: Right ventricular failure
  - id: HP:0033515
    label: opioid dependence
  - id: MONDO:0005632
    label: Acute chest syndrome in sickle cell disease
  - id: HP:0001945
    label: fever
  - id: HP:0001878
    label: Hemolytic anemia
  - id: CHEBI:6121
    label: ketamine
  - id: CHEBI:17303
    label: morphine
  - id: HP:0001744
    label: splenomegaly
  - id: HP:0031274
    label: hypovolemic shock
  - id: MAXO:0000110
    label: Vitamin D supplementation
  - id: HP:0100512
    label: Vitamin D deficiency
  - id: CHEBI:27300
    label: Vitamin D
  - id: CHEBI:28940
    label: Cholecalciferol
  - id: CHEBI:29016
    label: arginine
  - id: CHEBI:18211
    label: citrulline
  - id: CHEBI:3638
    label: chloroquine
  - id: CHEBI:50733
    label: nutritional supplements
  - id: MONDO:0005570
    label: Blood disorders
  - id: MONDO:0013517
    label: beta-thalassemia
  - id: HP:0002204
    label: Pulmonary embolus
  - id: HP:0100626
    label: end-stage liver disease
  - id: MONDO:0016363
    label: Iron overload diseases
  - id: HP:0012532
    label: Chronic pain
  - id: HP:0012432
    label: Chronic fatigue
  - id: MAXO:0010203
    label: echocardiography
  - id: HP:0002870
    label: obstructive sleep apnoea (OSA)
  - id: HP:0000520
    label: Proptosis
  - id: MAXO:0000004
    label: surgery
  - id: MAXO:0000058
    label: pharmacological treatment
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MONDO:0006079
    label: Acute chest syndrome (ACS)
  - id: HP:0002878
    label: Acute respiratory failure
  - id: HP:0012594
    label: Microalbuminuria
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003774
    label: End-stage renal disease
  - id: CHEBI:35457
    label: angiotensin-converting enzyme inhibitor
  - id: MAXO:0000652
    label: angiotensin-converting enzyme inhibitor therapy
  - id: HP:0000112
    label: kidney disease
  - id: MAXO:0000457
    label: Pain management
  - id: HP:0001903
    label: Anemia
  - id: CHEBI:18050
    label: L-glutamine
  - id: MAXO:0000827
    label: serum ferritin measurement
  - id: HP:0001875
    label: neutropenia
  - id: CHEBI:4356
    label: <desferrioxamine (DFO)
  - id: CHEBI:17941
    label: deferiprone (DFP)
  - id: CHEBI:49005
    label: deferasirox (DFX)
  - id: CHEBI:38157
    label: iron chelators
  - id: CHEBI:68554
    label: deferiprone
  - id: CHEBI:9144
    label: silymarin
  - id: MAXO:0000750
    label: conditioning regimens (fludarabine-thiotepa-treosulfan, busulfan-cyclophosphamide)
  - id: CHEBI:82557
    label: treosulfan
  - id: HP:0100602
    label: preeclampsia
  - id: HP:0001622
    label: preterm delivery
  - id: HP:0001511
    label: intrauterine growth restriction
  - id: CHEBI:50858
    label: corticosteroids
  - id: MAXO:0000618
    label: fluid replacement therapy
  - id: HP:0001919
    label: acute kidney injury
  - id: HP:0100639
    label: erectile dysfunction
  - id: CHEBI:71940
    label: Tadalafil
  - id: CHEBI:71942
    label: PDE5 inhibitors
  - id: MONDO:0019740
    label: Acquired thrombotic thrombocytopenic purpura (aTTP)
  - id: CHEBI:24261
    label: Glucocorticoids
  - id: MAXO:0000194
    label: Opioid therapy
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:35705
    label: immunosuppressive agents
  - id: HP:0003326
    label: Myalgia
  - id: HP:0002027
    label: Abdominal pain
  - id: HP:0002315
    label: Headache
  - id: MAXO:0001479
    label: allogeneic hematopoietic stem cell transplantation
  - id: HP:0002360
    label: Sleep disturbances
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001873
    label: Thrombocytopenia
  - id: CHEBI:28876
    label: Melphalan
  - id: CHEBI:61049
    label: Tacrolimus
  - id: CHEBI:44185
    label: Methotrexate
  - id: CHEBI:46195
    label: Acetaminophen
  - id: CHEBI:47381
    label: Diclofenac
  - id: HP:0000832
    label: Primary hypothyroidism
  - id: HP:0011787
    label: Central hypothyroidism
  - id: CHEBI:18248
    label: Iron
  - id: CHEBI:30660
    label: Thyroxine
  - id: HP:0001342
    label: Hemorrhagic strokes
  - id: HP:0002326
    label: Transient ischemic attack
  - id: MONDO:0044033
    label: Posterior reversible encephalopathy syndrome
  - id: HP:0001923
    label: hemolysis (reticulocytosis)
  - id: MONDO:0800385
    label: Iron overload
  - id: CHEBI:6456
    label: Lidocaine
  - id: CHEBI:75008
    label: <visual analog pain scale (VAS)>
  - id: CHEBI:41264
    label: busulfan (Bu)
  - id: HP:0025322
    label: Venous occlusive disease (VOD)
  - id: MONDO:0005399
    label: Venous thromboembolism (VTE)
  - id: HP:0002094
    label: dyspnea
  - id: MONDO:0007885
    label: Osteonecrosis of the Femoral Head (AVNFH)
  - id: HP:0000969
    label: Oedema
  - id: HP:0006554
    label: Acute Liver Failure
  - id: HP:0002098
    label: Respiratory distress
  - id: MAXO:0001175
    label: liver transplantation
  - id: MAXO:0010033
    label: umbilical cord blood transplantation
  - id: MAXO:0000068
    label: transplantation
  - id: CHEBI:17334
    label: penicillin
  - id: MAXO:0000066
    label: oxygen supplementation
  - id: HP:0002202
    label: pleural effusions
  - id: CHEBI:25805
    label: oxygen
  - id: HP:0002791
    label: alveolar hypoventilation
  - id: HP:0001395
    label: Liver fibrosis
  - id: MAXO:0035078
    label: Pulmonary function testing
  - id: HP:0001944
    label: dehydration
  - id: HP:0011105
    label: fluid overload
  - id: CHEBI:25107
    label: Magnesium
  - id: CHEBI:32599
    label: Magnesium sulphate
  - id: HP:0008209
    label: Premature ovarian insufficiency (POI)
  - id: HP:0011675
    label: Arrhythmias
  - id: HP:0012418
    label: Hypoxia
  - id: MAXO:0000118
    label: immunizations
  - id: MONDO:0100470
    label: Asthma
  - id: HP:0001627
    label: Cardiac abnormalities
  - id: CHEBI:119915
    label: fentanyl
  - id: CHEBI:16480
    label: nitric oxide
  - id: CHEBI:63533
    label: GnRH agonist
  - id: MAXO:0010314
    label: lung computed tomography
  - id: MAXO:0001490
    label: platelet transfusions
  - id: MAXO:0009003
    label: preimplantation genetic testing
  - id: MONDO:0011549
    label: Hyperhemolytic syndrome (HHS)
  - id: HP:0001896
    label: Reticulocytopenia
  - id: MONDO:0020380
    label: Sickle cell anemia (SCA)
  - id: HP:0001900
    label: Increased hemoglobin
  - id: CHEBI:35143
    label: Hemoglobin (Hb)
  - id: HP:0000739
    label: anxiety
  - id: HP:0100806
    label: Sepsis
  - id: MONDO:0018585
    label: Pediatric Arterial Ischemic Stroke
  - id: HP:0003270
    label: abdominal distension
  - id: HP:0002014
    label: diarrhoea
  - id: HP:0002573
    label: rectal bleeding
  - id: CHEBI:50249
    label: anticoagulant
  - id: CHEBI:5855
    label: Ibuprofen
  - id: MONDO:0000001
    label: disease
  - id: CHEBI:32026
    label: Poloxamer 188
  - id: MONDO:0004745
    label: Priapism
  - id: MAXO:0000527
    label: Physical examination
  - id: CHEBI:44915
    label: Propofol
  - id: CHEBI:28304
    label: Heparin
  - id: CHEBI:9449
    label: Terbutaline
  - id: HP:0004749
    label: atrial flutter
  - id: MAXO:0000503
    label: mechanical ventilation
  - id: MAXO:0000600
    label: renal replacement therapy
  - id: MONDO:0005098
    label: Stroke
  - id: MAXO:0000955
    label: noninvasive, bi-level positive airway pressure ventilation (BiPAP)
  - id: HP:0012592
    label: Albuminuria
  - id: HP:0001649
    label: Elevated heart rate
  - id: CHEBI:8455
    label: proguanil
  - id: MAXO:0001075
    label: Circumcision
  - id: HP:0100543
    label: cognitive dysfunction
  - id: HP:0001139
    label: High transcranial Doppler (TCD) velocities
